New hope for tough pancreatic cancer cases after first treatment fails
NCT ID NCT04752696
Summary
This study tested whether adding an experimental drug called onvansertib to standard chemotherapy could help people with advanced pancreatic cancer that had spread and stopped responding to their first treatment. It involved 41 participants who received the drug combination to see if it could shrink tumors and extend life. The goal was to find a better second-line option for this difficult-to-treat cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Phoenix
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
University of Kansas Medical Center
Westwood, Kansas, 66205, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.